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I n the EU, the legal status of agriculturalproducts resulting from the use of newbreeding techniques (NBTs)—among
others the new gene-editing technologies—
has been subject to dispute even before the
Court of Justice of the EU (CJEU) ruled that
products of newer forms of mutagenesis
should be regulated as genetically modified
organisms (GMOs; Breyer et al, 2009;
Abbott, 2015). In November 2019, the Coun-
cil of the EU requested the European
Commission (EC) to submit a study, and a
proposal if appropriate, for addressing the
legal status of novel genomic techniques
under Union law, and this will likely provide
more clarity for the products of NBTs. In the
meantime, several proposals for amending
the current GMO legislation have been
published. We here provide an analysis of
their respective key features, similarities and
differences, and potential implications of
their adoption.
Introduction
Much of the dispute on the legal status of
NBT products has centred on the scope of the
GMO definition. According to article 2(2) of
the Directive 2001/18/EC (hereafter: the
directive), a GMO is defined as “an organism,
with the exception of human beings, in
which the genetic material has been altered
in a way that does not occur naturally by
mating and/or natural recombination”
(Directive, 2001). This definition is further
supplemented in Annex I A Part 1 by a non-
exhaustive list of techniques that result in a
GMO. Additionally, Annex I A Part 2
comprises an exhaustive list of techniques
that are not considered to result in a GMO,
whereas Annex I B includes techniques, the
application of which results in genetic modifi-
cation, but whose products are exempted
from the provisions of the directive. The
latter include mutagenesis and cell fusion of
organisms that can exchange genetic material
through traditional breeding methods. The
exemptions were apparently made because
products of these techniques had already
been on the market for many years and with
a long safety record (Directive, 2001).
......................................................
“The exemptions were appar-
ently made because products of
these techniques had already
been on the market for many
years and with a long safety
record.”
......................................................
The scope of these exemptions has been
subject to plenty of discussions, in particular
regarding the products of genome editing
since many of these are the result of what is
scientifically considered as mutagenesis. The
concern is whether the exemption applies
only to techniques conventionally used when
the directive was adopted in 2001 or if it also
covers more recently developed techniques,
such as genome editing through site-directed
mutagenesis. The CJEU decided in Case C-
528/16 (CJEU 2018) that only organisms
obtained by techniques that have convention-
ally been used and have a long safety record
are exempted from the scope of the directive.
The position of the court is widely interpreted
as resulting in treating all gene-edited
organisms in the EU as regulated GMOs,
regardless of the nature of the change in their
genomes—whether they feature point muta-
tions or introduction of large fragments of
DNA, though there are also alternative and
more nuanced interpretations.
......................................................
“The position of the court is
widely interpreted as resulting
in treating all gene-edited
organisms in the EU as regu-
lated GMOs, regardless of the
nature of the change in their
genomes. . .”
......................................................
The judgement inspired several stake-
holders to publish proposals for amending
the current GMO legislation, though some
were published before 2018. Other earlier
proposals have suggested a complete elimi-
nation of the current legal framework for
GMOs in the EU and an entirely novel
approach focused on a trait-oriented frame-
work. These proposals are unrealistic in the
current political context—that is, it will be
impossible to build a political majority for
such an approach—and therefore not
included in our analysis. Some proposals are
rudimentary and simply argue that the legis-
lation should be changed as it is outdated or
has unacceptable consequences, while
others constitute standalone, detailed
legislative proposals. Using the presence of
concrete and elaborate details for legal
amendment as a criterion, we have selected
six proposals (Table 1) for analysis.
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Overview of the proposals
All of the analysed proposals envisage an
amendment rather than a total overhaul of the
GMO legislation, which is understandable given
the apparent urgency of the situation, in partic-
ular the fact that the current EU GMO legisla-
tion does not seem to be harmonised with that
of the major trade partners. Nevertheless, even
a minor change in the legislation may have
significant consequences. We have divided the
analysed proposals into two major groups:
proposals to alter the definition of a GMO and
proposals that amend the list of GMOs that are
exempted from the scope of the legislation.
......................................................
“All of the analysed proposals
envisage an amendment rather
than a total overhaul of the
GMO legislation, which is under-
standable given the apparent
urgency of the situation. . .”
......................................................
The German Leopoldina Academy (pro-
posal 1) (Leopoldina et al, 2019) suggests
either a direct change of the definition (art. 2
(2)) or an indirect change via the annex I A
part 2 (organisms not considered to be a
GMO). The term “GMO” should refer to an
organism, whose genetic material “(. . .) is
altered in the shape of insertion of genetic
information into the genome in a way that
does not occur naturally”. The consequences
would be twofold. First, the change of the
expression “has been altered” to “is altered
in the shape of insertion of genetic informa-
tion” is meant to remove an ambiguity in
the current definition, as it remains a point
of debate whether the currently used term
refers to the resulting genetic feature of the
organism or to the process by which the
organism’s genetic material has been modi-
fied. Second, the addition of “insertion of
genetic information” limits the scope of the
term “GMO” by excluding organisms featur-
ing deletions, regardless of size.
The proposal by AFBV and WGG (pro-
posal 2) (AFBV&WGG, 2020) also includes a
change of the definition of GMO, through
art. 2(2) and the Annex I A part 1, by classi-
fying genome editing as a technique leading
to genetic modification and by excluding
null segregants from the scope of the
directive. The proposal also includes amend-
ments to the exemptions from the scope of
the directive (new Annex I C).
The remaining examined proposals do
not redefine the legal term “GMO”, but aim
at limiting the scope of the directive by
changing contents of Annex I B or introduc-
ing new annexes. Such a change would
generally result in treating products of the
techniques listed there as GMOs that are
exempted from the provisions of the
directive.
According to the proposal of the Dutch
Government (proposal 3) (The Government
of Netherlands, 2017), exempted GMO prod-
ucts are those resulting from conventional
mutagenesis and cell fusion, similar to the
current legislation. In addition, plants result-
ing from techniques which do not involve
the introduction of other genetic material
than material from the same or crossable
plant species, as well as plants in which
recombinant DNA that was used for modifi-
cation are no longer present, should also be
exempted.
Another proposal by the Leopoldina (pro-
posal 4, provided in case the aforementioned
changes in the definition, i.e. proposal 1,
Table 1. The analysed legislative proposals and their respective main characteristics.





1 Deutsche Akademie der
Naturforscher Leopoldina
(Leopoldina et al, 2019)
Change in definition: only organisms
containing recombinant DNA are GMOs.
Null segregants, products of SDN1 and
SDN2 and cisgenesis are not GMO
All organisms Confirmation of status Academic
institution
2 Association Française des
Biotechnologies Végétales/
Wissenschaftlerkreis Grüne
Gentechnik e.V. (AFBV &
WGG, 2020)
Exclusion of null segregants.




that they had plants
in mind)
Confirmation of status NGO
3 The Government of the
Kingdom of Netherlands (The
Government of Netherlands,
2017)
Exemption of plants being products of
SDN1 and SDN2, cisgenesis/intragenesis
and null segregants.
Plants Justification after the




4 Deutsche Akademie der
Naturforscher Leopoldina
(Leopoldina et al, 2019)
Exemption of null segregants, products of
SDN1 and SDN2 and cisgenesis.
All organisms Confirmation of status Academic
institution
5 Grow Scientific Progress
(European Citizen’s Initiative,
2019)
Exemption of various products based on a




Notification procedure Group of
students
6 A coalition of Norwegian
experts coordinated by the
Norwegian Biotechnology
Advisory Board (Bratlie et al,
2019)
Tiered approach: Exclusion of null
segregants; products of genome editing
that could be achieved during
conventional breeding subject to
notification; products of cisgenesis/
intragenesis subject to expedited approval.
All organisms Depending on nature of
the changes
Expert body
GMO, genetically modified organism; NGO, non-governmental organisation; SDN, site-directed nuclease.
2 of 5 EMBO reports 21: e51061 | 2020 ª 2020 The Authors
EMBO reports Tomasz Zimny & Dennis Eriksson
would not be accepted) exempts “targeted
molecular techniques which, when applied,
effect a genetic modification that may have
occurred naturally”. Examples are tech-
niques that cause deletions of DNA;
exchange individual base pairs; do not cause
stable insertion of genetic information; or
cause the insertion, inversion or transloca-
tion in the genome of genetic information
known to occur; or can occur with high
probability in the natural gene pool of the
same species or closely related species.
In addition to amendments of the GMO
definition, proposal 2 also features addition
of a point 4 to the current Annex I A part 1
(techniques leading to genetic modification),
where genome editing techniques are
described as “a group of technologies that
allow the targeted modification of genetic
information by adding (insertion of), remov-
ing (deletion of), or exchanging (replace-
ment of) nucleotides at a specific location in
the genome of the recipient organism”. The
proposal also features a two-part addition to
Annex I C. The first part lists plants that
would be excluded from the scope of the
new directive, generally plants with alleles
edited so that they reproduce functionalities
present in their natural gene pools or func-
tionalities that can be obtained by sponta-
neous or induced mutagenesis or plants
with genes from their natural gene pool
inserted at a particular site. The second part
of the new Annex I C describes a new confir-
mation procedure, through which the appli-
cant would obtain official confirmation that
their product is not regulated.
A proposal from “Grow Scientific
Progress” (proposal 5; European Citizen’s
Initiative, 2019) introduces a clear distinc-
tion between conventional mutagenesis, the
products of which are exempted according
to Annex I B, and other types of genetic
modification, some of which would be
exempted according to a newly created
Annex I C. These exemptions would apply
to techniques that result in modifications
that could have been obtained by traditional
breeding methods or methods, “including
via breeding with other species with which
the resulting organism could naturally
exchange genetic material. Apart from this,
proposal 5 also includes details that are not
present in any of the other proposals: the
idea of a rigid definition of a long safety
record; and the concept of “traditional
breeding methods”. It also introduces a
mechanism of subjecting products of
conventional mutagenesis to risk assess-
ment, should a novel trait render the result-
ing organism a risk to human health or the
environment—which is currently missing
from the GMO legislation, since all products
of conventional mutagenesis are considered
safe and not subject to specific risk assess-
ment.
Bratlie et al (2019; proposal 6) introduce
a tiered system, whereby organisms with
temporary, non-heritable changes would be
exempted from the scope of the legislation,
while “genetically engineered organisms
with changes that exist or can arise naturally
and can be achieved using conventional
breeding methods” would be subject only to
a notification procedure and confirmation
that they meet the aforementioned criteria.
This tier “would apply to GMOs with genetic
changes that can also be obtained by
conventional methods, including substitu-
tion of an allele with another one that
already exists within the species, or muta-
tions that can arise naturally or by mutagen-
esis”. Products of cisgenesis would generally
fall into tier 2, subjected to expedited
approval, while organisms with genetic
changes that cross species barriers or that
involve artificial DNA would be subject to a
full authorisation procedure including risk
assessment. The authors also propose that
all GMOs should be subject to assessment of
“societal benefit, sustainability and ethics”,
as is the case with the current GMO authori-
sation procedure in Norway.
The presented proposals have various
features in common. All generally strive to
address the lack of clarity associated with
the regulatory status of the products of
NBTs. The similarity between the Dutch
proposal from before the CJEU’s judgement
and the others is a good example of how
the Court’s decision stimulated activity in
this respect, even though the regulatory
status of such organisms was not clear
before the court decision. The analysed
proposals also aim at a step towards liberal-
isation in the legislation by either excluding
or exempting generally described group(s)
of organisms from the provisions of the
directive.
Exclusion versus exemption
The most significant difference between the
analysed proposals is the distinction
between amending the GMO definition and
expanding the list of exemptions. This
would have profound consequences: an
organism which is not classified as a GMO,
has the same legal status as an organism
developed through any conventional tech-
nique. This means that member states have
very limited, if any, means for restricting its
development or commercialisation. By
contrast, an exemption does not protect the
products of an exempted technique from
being subjected to national restrictions, as
ruled by the CJEU. In fact, this right has
already been exercised: in a recent judge-
ment, the French Conseil d’État mandated
that plants developed through random muta-
genesis performed on in vitro cultures shall
be subject to the legal provisions that apply to
GMOs, rather than being exempted as all





judgement is currently in the process of
being implemented into French national
law. As such, changes in the directive may
either provide for legal certainty and stabil-
ity for breeders or may become a source of
another set of disputes as to whether a
particular product will be regulated. The dif-
ference between an exclusion and an exemp-
tion may therefore have serious
consequences for academia and industry.
......................................................
“. . . an exemption does not
protect the products of an
exempted technique from being
subjected to national restric-
tions, as ruled by the CJEU.”
......................................................
Similarly, an amendment may influence
the possibility of conducting field trials. If a
plant is considered to be a regulated GMO,
any field trials are regulated by national
provisions on the basis of the Directive.
These procedures are costly—significantly
so for public researchers with minor budgets
—and, depending on the country, rather
restrictive. Excluding groups of organisms
from the directive via a redefinition of GMO
would therefore impact field trials as well,
whereas exempting those organisms would
again allow member states to introduce
national restrictions.
Deregulation of certain groups of organ-
isms would also influence the innovation
ª 2020 The Authors EMBO reports 21: e51061 | 2020 3 of 5
Tomasz Zimny & Dennis Eriksson EMBO reports
potential of academia. Researchers would
know that certain organisms or the use of
certain techniques would be more easily
transferable to the commercial sector than
regulated ones. Again, given the potential of
national restrictions, the difference between
exclusions and exemptions is clearly visible,
since any of the exempted organisms may
still face national restrictions.
Scope of proposed deregulation
Another aspect is the biological scope of
planned exclusions or exemptions. The discus-
sion in general seems to be revolving about
potential deregulation of plants, in particular
crop species used in agriculture. Hence, some
of the proposals—in particular proposals 2, 3,
5—limit the scope of the deregulation, either
by indicating particular groups of organisms
or even particular traits. The remaining
proposals do not contain such restrictions. The
biological scope of deregulation could be a
“deal breaker” when it comes to assessing the
conformity of proposed solutions with the
precautionary principle. GM plants may
spread, for instance through pollen flow, but
highly selected crop species usually require
high maintenance and would likely not be
competitive in the natural environment.
Hence, one might argue that the deregulation
of such crop plants would not necessarily
elevate environmental risks above acceptable
levels. If, in contrast, the deregulation would
apply to all organisms, it could be argued that
in many cases—gene-edited insects, fish and
other organisms—their spread in the environ-
ment could lead to potential risks that would
be difficult to control. One has to bear in mind
that laws have general application: once
enacted, there is little room for restrictive or
narrow interpretation. As such, the scope of
deregulation, that is which organisms, regard-
less of technique, will be deregulated, should
be taken into consideration.
......................................................
“The biological scope of dereg-
ulation could be a “deal
breaker” when it comes to
assessing the conformity of
proposed solutions with the
precautionary principle.”
......................................................
If a group of organisms were to be
excluded from the scope of the legislation,
then such organisms would be treated in the
same way as conventionally bread organ-
isms. In particular, such organisms would
not be subjected to risk assessment and
authorisation procedures, which would
improve the commercial potential of tech-
niques through which such excluded or
exempted organisms are produced and
broaden the spectrum of technologies EU
breeders can use. Currently, developing
organisms that face GMO authorisation
procedures constitutes an investment risk,
given the uncertain outcomes of these proce-
dures, their cost and length, and possible
national restrictions by member states.
Furthermore, food and feed products
developed from such organisms would not
have to be labelled as GMOs. This would
have consequences for the farmers too.
Since the accidental admixture thresholds
(currently up to 0,9%) and unauthorised
GMO thresholds (currently 0% with some
limited exemptions) would not apply to
deregulated organisms, farmers would not
need to be subjected to co-existence restric-
tions, whose major objective is to prevent
adventitious presence and cross-pollination
with regulated GMOs. Again, exclusion of
certain organisms from the scope of the
legislation would result in a rather broad
freedom to use them EU-wide, whereas an
exemption would still allow individual EU
member states to introduce local restric-
tions.
Finally, exclusion or exemption of certain
groups of organisms or techniques will also
influence international trade with the EU. It
will bring EU legislation more in line with
the regulatory provisions of some of its
major trading partners, who have deregu-
lated such organisms, notably the United
States, Canada or Argentina. Without such
harmonisation, trade in agricultural products
may be hampered by asynchronous or asym-
metric authorisation, since gene-edited plant
products not regulated in their countries of
origin could still be treated as unauthorised
GMOs with zero tolerance policy in the EU.
Lack of such harmonisation will also put a
strain on the phytosanitary and customs
authorities, who will be obligated to prevent
the influx of such organisms into the EU
while facing objective difficulties with their
detection and tracking. Member states, who
decide to introduce national limitations on
exempted products will have to find reason-
able ways to enforce such limitations, which
may prove difficult in practice.
Certainty of law
The disputes on the regulatory status of NBT
products originated mostly from the ambigu-
ity of the legislation that led to differences in
interpretation. All analysed proposals aim
for more clarity and balance in the legisla-
tion by excluding or exempting techniques,
whose products they consider to be compa-
rable in terms of associated risks with prod-
ucts that are already not GMO-regulated.
The analysed proposals strive to increase
the legal certainty and strike a new balance
between ensuring a proper level of safety
and freedom to conduct research and devel-
opment. Currently, the weight of the legisla-
tion is shifted strongly towards precaution
and safety.
Nevertheless, problems may arise from
the use of terms with vague or not
commonly accepted meanings, such as
“closely related species” or “conventional
breeding”. Their use, without proper defi-
nition, may result in problems not unlike
those that are caused by the current wording
of the exemptions in the directive. The
proposals are drafted by scientists (propos-
als 1, 2, 4), science students (proposal 5) or
experts that likely have a strong scientific
background (proposals 3 and 6), who proba-
bly find certain terms clearly understand-
able. However, once put into law, they will
be interpreted by lawyers, who might find
other ways to interpret them. Would for
example rye be considered a closely related
species of wheat? Or is randomly induced
mutagenesis performed on in vitro cell
cultures considered conventional? This situ-
ation may lead to further disputes. It will
also be important to measure the proposals
against relevant basic principles of EU law,
such as the proportionality principle, the
innovation principle and the precautionary
principle.
......................................................
“. . . a need for a more trans-
parent and less ambiguous
authorisation system can be
noticed throughout the anal-
ysed proposals.”
......................................................
Some of the proposals therefore suggest a
pre (the Norway proposal)- or post (the
Dutch proposal)-marketing authorisation
system limited to confirming the status of a
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given product. Proposal 6 (Bratlie et al,
2019) stands out here, as it provides not
only for an expedited authorisation process
for intragenic or cisgenic organisms, but also
an assessment of “societal benefit, sustain-
ability and ethics” for organisms with herita-
ble changes. The latter solution may lower
the certainty of law again by subjecting
products to assessment based on non-scien-
tific criteria. Regardless of these details, a
need for a more transparent and less
ambiguous authorisation system can be
noticed throughout the analysed proposals.
Concluding remarks
It is clear that the analysed proposals pursue
similar goals such as easing the administra-
tive burdens connected with the authorisa-
tion of some organisms, but they pursue
them through different methods. This shows
that, at least, the scientific community in the
EU shares a common goal even if the
proposals are not always compatible with
each other in the sense that they either
would affect different types of organisms or
propose amendments with starkly different
consequences. The lack of a common stance
from the scientific community or from other
stakeholders might therefore increase confu-
sion regarding the preferred way forward.
It is currently unclear, whether the EC
will conclude its analysis of the legal status
of novel genomic techniques with an infer-
ence that a revision of the GMO legislation is
in order. Prima facie, a revision seems justi-
fied given the counter-intuitive conse-
quences of the current status quo—
regulating organisms with more controlled
genetic changes more strictly than organ-
isms with more randomly introduced genetic
changes, such as products of conventional
mutagenesis—and the pressure from the
scientific community and other stakehold-
ers. Should the EC decide that a revision is
necessary, the analysed proposals may indi-
cate the direction in which such a revision
might go.
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